BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market.
BalinBac started working on coronavirus drug solutions in January 2020 when the team predicted the impact of the COVID-19 pandemic.
Our scientists and therapeutics development executives have a wealth of working knowledge in the pharmaceutical industry and have a track record of successfully bringing key antiviral and antibacterial drugs to market. We know how to rapidly get drugs to patients and what it takes to get this work done quickly.
CEO John Gregg has over 35 years in the pharmaceutical industry and his past start-ups have successfully brought new anti-infective drugs to market. John Gregg is uniquely qualified as he was previously responsible for new product planning for Pfizer for its picorna virus/rhino virus/coronavirus R&D program.
John Gregg, MBA
President & CEO
Symbiomix, AkaRx, Pfizer, Novartis, J&J, BMS
Start-up and pharmaceutical industry veteran, John M.H. Gregg, has extensive experience in forming and successfully exiting microbiome companies for investors. His expertise is in worldwide clinical development and commercialization of microbiological products, new anti-infectives, and oncology drugs, most recently with an FDA approval in September 2017 of Solosec (secnidazole). He has spent much of his career directing the commercialization efforts for a large number of antibiotic, anti-protozoal, anti-fungal and anti-viral drugs as well as therapeutics in multiple other therapeutic areas, including immunology and oncology. He is an industry leader in biotech company development, serving as CEO of specialty infectious disease and microbiome modulation companies like his current company, BalinBac (Balance in Bacterial Species) Therapeutics, and his prior microbiome start-up, Symbiomix Therapeutics.
Mr. Gregg established his reputation in senior marketing and new product planning roles at leading large drug companies including Pfizer, Novartis, Johnson & Johnson, and Bristol-Myers Squibb. In big pharma, Mr. Gregg led global development planning teams for pipeline compounds at all phases of development.
Mr. Gregg successfully launched Symbiomix Therapeutics, LLC, and LifeQual Pharmaceuticals, Inc., where he was the founding CEO. He was Executive Director of Commercial Operations for AkaRx, an oncology spinout of Astellas Pharma. He sold AkaRx in a successful 15X return M&A transaction exit to Eisai Pharma. The resulting AkaRx drug, Doptelet (avotrombopag) launched in 2018 by Dova Pharmaceuticals.
Mr. Gregg holds a B.A. degree in biology (microbiology focus) from the University of Chicago and an M.B.A. in Marketing and International Business from the Leonard Stern School of Business at New York University. He is a member of the American Society of Microbiology, the American Society of Clinical Oncology, the American Society of Hematology, The American Chemical Society, the American Society of Pharmaceutical Scientists, and LES Certified Licensing Professional (CLP).
Bruce has worked across a wide range of pharmaceutical commercialization strategy, analysis, and implementation over the past 28 years at Pfizer and McKinsey. At Pfizer, he led the Management Science Group and the Resource Allocation Group where besides supporting sales and marketing optimization, he worked with business development and commercial development. He played key roles on various co-promotion deals including Lipitor, Celebrex, Spiriva, and Eliquis, especially negotiating promotion resource levels. Prior to pharmaceuticals, Bruce gained significant corporate finance experience with Morgan Stanley, Stern Stewart, and McKinsey. Bruce holds an MBA from the University of Chicago, and Bachelor of Science in Civil Engineering from the Massachusetts Institute of Technology.